Pleiotropic effects of telmisartan: Still more to come?

Journal of Hypertension

Volumn 26, Issue 5, 2008, Pages 854-856

  Benndorf, Ralf A ^a   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; RAPAMYCIN; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG ELUTING STENT; DRUG INHIBITION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; PATHOPHYSIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; STROKE; VASCULAR SMOOTH MUSCLE;

EID: 42049103473     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f76481     Document Type: Editorial

References (27)

1. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355:637-645.
2. Schwabe U, Paffrath D. 2006 Report on drug prescription. New York: Springer Publishing Group, 2006. pp. 247-272.
3. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease: six-year follow-up experience. The Framingham Study. Ann Intern Med 1961; 55:33-50.
4. Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991; 338:419-423.
5. Laragh JH, Baer L, Brunner HR, Buhler FR, Sealey JE, Vaughan ED Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
6. Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol 1976; 38:786-800.
7. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006; 103:17985-17990.
8. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52:11-34.
9. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460.
10. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990; 137:7-12.
11. Ford CM, Li S, Pickering JG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol 1999; 19:1843-1851.
12. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330:1431-1438.
13. Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens 2006; 8:99-105.
14. Schupp M, Janke J, Clasen R, Unger T, Kinscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109:2054-2057.
15. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43:993-1002.
16. Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens 2008; 26:973-980.
17. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin- aldosterone system. J Cardiovasc Pharmacol 1992; 20 (Suppl 1):S48-S54.
18. Bajcetic M, Benndorf RA, Appel D, Schwedhelm E, Schulze F, Riekhof D, et al. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol 2007; 47:295-304.
19. Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55:1159-1164.
20. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29:849-856.
21. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 2002; 277:9268-9277.
22. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24:392-397.
23. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Anti-inflammatory and antioxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2007 [Epub ahead of print]
24. Kappert K, Sparwel J, Sandin A, Seiler A, Siebolts U, Leppänen O, et al. Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in restenosis. Arterioscler Thromb Vasc Biol 2006; 26:2644-2651.
25. Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 2006; 26:2462-2468.
26. Hong SJ, Shim WJ, Choi JI, Joo HJ, Shin SY, Park SM, et al. Comparison of effects of telmisartan and valsartan on late lumen loss and inflammatory markers after sirolimus-eluting stent implantation in hypertensive patients. Am J Cardiol 2007; 100:1625-1629.
27. Anderson C. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme. J Int Med Res 2005; 33 (Suppl 1):50A-57A.